Thor Medical - Småprat '22 (NANOV) 4

[TekBot]

Flagging Thor Medical ASA 11 April 2025

11.4.2025 18:27:35 CEST | Thor Medical ASA | Major shareholding notifications

Oslo, 11 April 2025
…

Vis børsmeldingen

Ludvik Sandnes, Chairman of the Board at Thor Medical ASA (the “Company”), has
received proxies without voting instructions to vote for a total of 15,786,906
shares at the Company’s Annual General Meeting on 24 April 2025, representing
approx. 5.00 percent of all shares in the Company. Additionally, Sandnes has
received proxies with voting instructions to vote for a total of 3,046,978
shares at the Company’s Annual General Meeting on 24 April 2025, representing
approx. 0.97 percent of all shares in the Company.

Furthermore, Sandnes owns 626,489 shares, representing approx. 0.20 percent of
all shares issued in the Company, as well as 300,000 shares, representing
approx. 0.10 percent of all issued shares in the Company through Ekornhuset AS.
Sandnes will be able to cast votes at the Annual General Meeting for a total of
19,760,375 shares, representing approx. 6.27 percent of all issued shares in the
Company.

The received proxies are valid only for the aforementioned General Meeting and
will automatically expire, so that after the General Meeting, Sandnes will own
926,489 shares in the Company, including the shares owned by Ekornhuset AS.

This notification is issued because Sandnes has been granted proxies without
voting instructions for more than 5% of all voting rights in the Company. The
notification does not indicate that the aforementioned is the final number of
shares Sandnes will be able to vote for at the Annual General Meeting.

This information is subject to disclosure requirements pursuant to Section 4-2
of the Securities Trading Act.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18495673/5936/Download%20announce
ment%20as%20PDF.pdf

Kilde

[TekBot]

Thor Medical ASA: Completion of annual general meeting

24.4.2025 15:03:03 CEST | Thor Medical ASA | Additional regulated information
required to be disclosed under the laws of a member state

…

Vis børsmeldingen

Oslo, Norway, 24 April 2025

The annual general meeting in Thor Medical ASA (the “Company”) was held today,
24 April 2025. All items on the agenda were approved in accordance with the
notice. The minutes are attached hereto and are also available on
https://www.thormedical.no/.

DISCLOSURE REGULATION

This information is required to be disclosed under Section 5-12 of the
Securities Trading Act.

CONTACTS

Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’. To learn
more, visit www.thormedical.no - http://www.thormedical.no

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18503732/5972/Download%20announce
ment%20as%20PDF.pdf

Thor Medical ASA - Minutes from ordinary general meeting 24 April 2.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18503732/5971/Thor%20Medical%20AS
A%20-%20Minutes%20from%20ordinary%20general%20meeting%2024%20April%202.pdf

Kilde

[TekBot]

Thor Medical - Grant of restricted stock units (RSU) to the members of the board

2.5.2025 19:55:48 CEST | Thor Medical ASA | Additional regulated information
required to be disclosed under the laws of a member state

…

Vis børsmeldingen

Oslo, Norway, 2 May 2025

Reference is made to the stock exchange announcement made by Thor Medical ASA
(the “Company”) the Company on 24 April 2025 whereby it was disclosed that the
Company’s annual meeting resolved (“AGM”), among other things, the approval of a
restricted share units (“RSU”) program.

At the AGM, the shareholders approved the remuneration to the Company’s current
board of directors whereby the board members were given the choice to receive
their remuneration, or a part thereof, for the period from the AGM to the annual
general meeting of 2026, in the form of restricted share units (“RSU”), as a
part of the Company’s RSU program. The allocation of RSUs has today been made.

The number of RSUs allocated to each board member has been determined based on
the NOK value for the RSU-selected portion of the total compensation for the
board member. The compensation is divided by the subscription price of NOK
2.4295, equal to the 10-day volume weighted average prior the general meeting. A
total of 274,401 RSUs has been allocated to the following board members:

• Mimi Kristine Berdal: 54,880 RSUs
• Thomas Ramdahl: 54,880 RSUs
• Jens Gisle Schnelle: 164,641 RSUs

Primary insider notifications pursuant to the market abuse regulation article 19
are attached. This information is required to be disclosed under Section 5-12 of
the Securities Trading Act.

CONTACTS

Brede Ellingsæter, CFO & COO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.

To learn more, visitwww.thormedical.no - http://visitwww.thormedical.no -
https://www.thormedical.no.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18514604/6040/Download%20announce
ment%20as%20PDF.pdf

Kilde

[TekBot]

Thor Medical - Primary insider notifications - Grant of restricted stock units (RSU) to the members of the board

2.5.2025 23:06:46 CEST | Thor Medical ASA | Additional regulated information
required to be disclosed under the laws of a member state

…

Vis børsmeldingen

Oslo, Norway, 2 May 2025

Reference is made to the stock exchange announcement made by Thor Medical ASA
(the “Company”) the Company on 2 May 2025 regarding the grant of restricted
share units (“RSU”) to members of the board of directors.

Primary insider notifications pursuant to the market abuse regulation article 19
are attached hereto. This information is required to be disclosed under Section
5-12 of the Securities Trading Act.

CONTACTS

Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.

To learn more, visitwww.thormedical.no - http://visitwww.thormedical.no -
https://www.thormedical.no.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18514642/6044/Download%20announce
ment%20as%20PDF.pdf

Jens Gisle Schnelle - Primary insider notifications.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18514642/6041/Jens%20Gisle%20Schn
elle%20-%20Primary%20insider%20notifications.pdf

Mimi K Berdal - Primary insider notifications.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18514642/6042/Mimi%20K%20Berdal%2
0-%20Primary%20insider%20notifications.pdf

Thomas Ramdahl - Primary insider notifications.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18514642/6043/Thomas%20Ramdahl%20
-%20Primary%20insider%20notifications.pdf

Kilde

[Georg]

Oslo (Infront TDN Direkt): Arctic Securities tar opp dekning på Thor Medical med kjøpsanbefaling og et kursmål på 4,0 kroner pr aksje.

[JMA73]

Dette innlegget ble rapportert og er midlertidig skjult.

[Pk2k]

@JMA73

we believe the undisclosed strategic partner is Bayer, a global leader in radiopharmaceuticals.

Den setningen der

[Oilimp]

Sliter med å skjønne hvorfor dette innlegget er skjult? @pdx ?

[pdx]

I analysen står det: “It may not be reproduced, redistributed or republished by any recipient for any purpose or to any person. If you are not a client of Arctic, you are not entitled to receive the report.”

[Savepig]

Bedre å gjengi slike pressemeldinger:

THOR MEDICAL: ARCTIC TAR OPP DEKNING MED KJØP, KURSMÅL 4,0

i dag kl. 08:13 ∙ TDN Finans

Oslo (Infront TDN Direkt): Arctic Securities tar opp dekning på Thor Medical med kjøpsanbefaling og et kursmål på 4,0 kroner pr aksje.

Det fremgår av en analyse fra meglerhuset mandag.

Arctic mener markedet undervurderer Thor Medicals potensial, ettersom dagens aksjekurs innebærer begrenset tro på selskapets kommersielle suksess.

“Vi ser flere triggere for aksjen fremover, inkludert ekspansjonsplaner for AlphaOne, som indikerer at etterspørselen allerede overstiger forventet kapasitet”, skriver meglerhuset.

---

Jeg mener som vanlig at slike analyser ikke engang kan brukes til å tørke seg bak med, og ikke bare fordi det kun foreligger digital.

[Investor]

@Georg

Oslo (Infront TDN Direkt): Arctic Securities tar opp dekning på Thor Medical med kjøpsanbefaling og et kursmål på 4,0 kroner pr aksje.

Trodde AS hadde sluttet med dekning på helsekasjer for en god stund siden. Kan dette bety at en emi er nært forestående.

[JMA73]

Du følger tydeligvis ikke med!! Thor Medical har akkurat hatt emisjon og har full finansiert bygging av Alpha One fabrikken til cash positiv. TM har heller ikke betalt noe for analysen.

[TekBot]

Thor Medical sign strategic supply agreement for feedstock of thorium

13.5.2025 16:45:01 CEST | Thor Medical ASA | Inside information

Oslo13 May 2025: Thor Medical ASA, a leading emerging supplier of alpha-emitters
…

Vis børsmeldingen

for next-generation precision cancer treatment, has signed an agreement securing
supply of thorium feedstock from a major European multinational chemical
manufacturing company.

The three-year supply agreement strengthens the already strong partnership
between the two companies and secures feedstock supplies for Thor Medical’s
production of radioisotopes at its current pilot plant and its commercial scale
plant under construction, AlphaOne.

"Thor Medical is on a strong trajectory to become a global leader in
alpha-emitting isotopes for next-generation cancer care. This rapidly emerging
field within radiopharmaceuticals holds the promise to transform treatment for
millions of cancer patients worldwide. Together with our customers and
suppliers, we are establishing a sustainable and resilient value chain that is
essential to unlocking this potential and capturing a significant share of a
highly attractive global market, "says Jasper Kurth, CEO of Thor Medical.

Thor Medical has already signed sales agreements with several
radiopharmaceutical companies with late-stage cancer therapeutic candidates
based on alpha-emitting lead-212 isotopes.

The supply agreement with the undisclosed partner is part of Thor Medical’s
strategy of developing multiple feedstock suppliers as part of its value chain.
Thor Medical last year announced an MoU with Steenkampskraal Holdings Ltd in
South-Africa for future supplies of feedstock from the Steenkampskraal Monizite
Mine in the Western Cape which has among the highest concentrations of rare
earth elements and thorium globally.

CONTACT

Brede Ellingsæter, CFOO Thor Medical, +47 472 38 440,
brede.ellingseter@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of alpha particle emitters produced from
naturally occurring thorium. Its proprietary production process requires no
irradiation or use of nuclear reactors, and provides reliable, environmentally
friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical
industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange under the ticker symbol ‘TRMED’.

IMPORTANT INFORMATION

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to Section 5-12 the Norwegian Securities Trading Act. The stock
exchange announcement was published by Brede Ellingsæter, CFOO, Thor Medical
ASA, at the time and date stated above in this announcement.

This release contains forward -looking information and statements relating to
the business, performance, and matters that may impact the results of Thor
Medical. Forward-looking statements are statements that are not historical facts
and may be identified by words such as “aims,” “anticipates,” “believes,”
“estimates,” “expects,” “foresees,” “intends,” “plans,” “predicts,” “projects,”
“targets,” “potential,” and similar expressions. Such forward-looking statements
are based on current expectations, estimates, and projections, reflect current
views concerning future events, and are subject to risks, uncertainties, and
assumptions, and may be subject to change without notice. Forward-looking
statements are not guarantees of any future performance, and risks,
uncertainties, and other important factors could cause the actual business,
performance, results, or the industry and markets in which Thor Medical operates
to differ materially from the statements expressed or implied in this release by
such forward-looking statements. No representation is made that any of these
forward-looking statements or forecasts will come to pass or that any forecasted
performance, capacities, or results will be achieved, and you are cautioned not
to place any undue reliance on any forward-looking statements.

This release is for information purposes only and is not to be relied upon in
substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18527407/6092/Download%20announce
ment%20as%20PDF.pdf

Kilde

[TekBot]

Flagging – Thor Medical ASA – passerer 5?%

Richard Felix Heinrich har per 5. juni 2025 passert flaggegrensen på 5 % i Thor Medical ASA (ISIN: NO0010597883).
Etter gjennomføring av flere aksjetransaksjoner eier Heinrich totalt 18 000 000 aksjer i selskapet, tilsvarende 5,73 % av selskapets 314 408 521 utestående aksjer og stemmer.
Av dette eies:
…

Vis børsmeldingen

• 3 000 000 aksjer direkte av Richard Felix Heinrich
• 15 000 000 aksjer gjennom hans heleide selskap Olili AS (org.nr. 925 582 727)
Eierandel før transaksjonene: under 5 %
Eierandel etter transaksjonene: 5,73 %
Transaksjonsdato: 5. juni 2025

Kilde

[Hotdog]

Richard felix heinrich virker som en ryddig kar med god snute for en god business.
https://www.dn.no/mat/backstube/richard-felix-heinrich/matthias-bresser/ga-seg-som-aksjeanalytiker-na-omsetter-han-gjarbakst-for-flere-hundre-millioner-med-studiekameraten/2-1-1438552

[TekBot]

Thor Medical signs strategic sales agreement for Thorium-228 with global leader in targeted alpha therapy

16.6.2025 07:30:00 CEST | Thor Medical ASA | Inside information

Oslo, 16 June 2025: Thor Medical ASA, a leading emerging supplier of
…

Vis børsmeldingen

alpha-emitters for next-generation precision cancer treatment, has signed a
strategic agreement for supply of Thorium-228 to a global leader in targeted
alpha therapy.

The five-year supply agreement represents revenues of approximately NOK 200
million (USD 20 million) for Thor Medical, with a phased ramp-up of supply in
accordance with the planned commissioning and scaling of the company’s AlphaOne
plant, currently under construction.

Thorium-228 is a precursor for Pb-212, which is widely regarded as one of the
most promising radioisotopes for use in next-generation precision cancer
treatments.

“We are proud to supply a global frontrunner in targeted alpha therapy and to
contribute to a broad clinical program aimed at tackling some of the most
challenging cancers. This agreement further validates the growing momentum and
accelerating demand for alpha-emitting radiotherapeutics and the strategic role
Thorium-228 will play in the future of precision oncology,” says Jasper C.
Kurth, CEO of Thor Medical.

The undisclosed partner is progressing an extensive portfolio of targeted alpha
therapy programs, including advanced-stage candidates addressing a variety of
solid tumors.

AlphaOne, Thor Medical’s first commercial-scale facility for high-quality
radioisotopes entered construction in April following a final investment
decision at the end of March. The plant will be fully operational in Q3 2026…

“Global demand for alpha-emitting isotopes is outpacing available and planned
capacity, and we are actively scaling to meet this need. Through process
innovation and continuous debottlenecking at AlphaOne, we are positioning Thor
Medical to reliably support the growing clinical and future commercial demand,”
says Jasper C. Kurth, CEO of Thor Medical.

The agreement represents Thor Medical’s fourth commercial supply agreement,
adding to long-term supply agreement for Thorium-228 with ARTBIO and AdvanCell,
and a supply agreement for Pb-212 for preclinical use with a big pharma company.

CONTACT

Brede Ellingsæter, CFO & COO Thor Medical, +47 472 38 440,
brede.ellingseter@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of alpha particle emitters produced from
naturally occurring thorium. Its proprietary production process requires no
irradiation or use of nuclear reactors, and provides reliable, environmentally
friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical
industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange under the ticker symbol ‘TRMED’.

IMPORTANT INFORMATION

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to Section 5-12 the Norwegian Securities Trading Act. The stock
exchange announcement was published by Brede Ellingsæter, CFOO, Thor Medical
ASA, at the time and date stated above in this announcement.

This release contains forward -looking information and statements relating to
the business, performance, and matters that may impact the results of Thor
Medical. Forward-looking statements are statements that are not historical facts
and may be identified by words such as “aims,” “anticipates,” “believes,”
“estimates,” “expects,” “foresees,” “intends,” “plans,” “predicts,” “projects,”
“targets,” “potential,” and similar expressions. Such forward-looking statements
are based on current expectations, estimates, and projections, reflect current
views concerning future events, and are subject to risks, uncertainties, and
assumptions, and may be subject to change without notice. Forward-looking
statements are not guarantees of any future performance, and risks,
uncertainties, and other important factors could cause the actual business,
performance, results, or the industry and markets in which Thor Medical operates
to differ materially from the statements expressed or implied in this release by
such forward-looking statements. No representation is made that any of these
forward-looking statements or forecasts will come to pass or that any forecasted
performance, capacities, or results will be achieved, and you are cautioned not
to place any undue reliance on any forward-looking statements.

This release is for information purposes only and is not to be relied upon in
substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18565350/6196/Download%20announce
ment%20as%20PDF.pdf

Kilde

[hybrid]

Lækkert!

[hybrid]

@TekBot

The agreement represents Thor Medical’s fourth commercial supply agreement,
adding to long-term supply agreement for Thorium-228 with ARTBIO and AdvanCell,

Ikke verst.

[hybrid]

frekkaz det der.

[Bingo123]

Fremstår som en av de mest spennende casene på oslo børs dette. En helt annerledes farma aksje som faktisk melder om skikkelige avtaler allerede.